The Institute is a government supported entity that promotes the
development of high technology companies and technologically advanced products.
The Institute will provide Harbin First Bio-Engineering Pharmaceutical Company
subsidiary with the title "Disease Kits Technology Research and Development
Center" as well as additional support and benefits, including a permanent 15%
tax on the sale of new products (the normal tax is 25%), and a subsidy of
Harbin First Bio-Engineering Pharmaceutical Company is the only research
and development center for external use disease testing kits in
"China Sky One is honored to receive this prestigious award for its
research and development ability from the Science and Technology Institute of
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a
Safe Harbor Statement
Certain statements made in the press release constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements can be identified by the use of forward-looking
terminology such as "believe," "expect," "may," "will," "should," "project,"
"plan," "seek," "intend," or "anticipate" or the negative thereof or
comparable terminology. Additional statements that are necessarily forward
looking in nature also include, without limitation, statements relating to our
research and development activities, expected revenues or sales margins,
results of recent acquisitions and our ability to increase sales and expand
our presence in the global market place, and risks or uncertainties relating
to PRC socioeconomic issues. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
our future plans, objectives or performance. The Company cannot provide any
assurance that it will be able to establish listing of its securities on any
national or regional securities exchange or market system. Actual results
could differ materially from the expectations reflected in such forward-
looking statements as a result of a variety of factors, including the
inability of the company to meet listing standards of an exchange, risks
associated with the effect of changing economic conditions in
For more information, please contact:
China Sky One Medical, Inc.
Ms. Yanwei Zhang, Board Secretary
Tel: +86-451-53994069
Email: cntiandiren@yahoo.com.cn
CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
Website: http://www.ccgelite.com
SOURCE China Sky One Medical, Inc.